Companies Cryptocurrencies
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Exchange: Nasdaq Global Select
IPO Date: 01/01/1991
CEO: Dr. Leonard Schleifer
Biotechnology Healthcare 🔗
  • REGN
  • 589.32
  • 64734445568
    market cap
  • -6.080017
If you bought

shares of Regeneron Pharmaceuticals Inc (REGN) on
You would have made
Old Price $12 Current Price $12

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 7,400 full-time employees. The firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The firm’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Address: 777 Old Saw Mill River Rd Tarrytown NEW YORK 10591

Stay updated.